GENB
Generate Biomedicines, Inc.
NASDAQ · Financial Services · Asset Management · US
$16.39
+0.31%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
$2.10B
MomentumView details →
1D Return
+0.31%
YTD Return
—
RSI (14)
54.5
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.2x
Market Cap
$2.10B
RSI (14)
54.5
MomentumView details →
1D Return
+0.31%
YTD Return
—
Similar companies
American Century Disciplined Value InvBIGRXT. Rowe Price Spectrum Moderate Allc InvTRPBXOxford Lane Capital Corp. 6.75% Notes due 2031OXLCLColumbia Acorn International InstACINXOxford Lane Capital Corp. 5.00% Notes due 2027OXLCZOxford Lane Capital Corp. 7.95% Notes due 2032OXLCGFind similar companies →
Latest newsMore news →
Generate Biomedicines Inc's post-IPO lock-up period is set to expire on Wednesday, allowing insiders, early investors, and major shareholders to sell shares from its $400 million IPO.11d agoGenerate Biomedicines Inc. reported its second quarter 2026 financial results, including cash, cash equivalents, and marketable securities of approximately $457.4 million as of June 30, 2026.30d ago